IGF-1 and retinopathy

被引：1

作者：

Smith, Lois E. H. ^{[1
]}

机构：

[1] Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA

来源：

RETINAL AND CHOROIDAL ANGIOGENESIS | 2008年

关键词：

D O I：

10.1007/978-1-4020-6780-8_7

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Retinopathy continues to be a major cause of blindness in children (retinopathy of prematurity, ROP), in adults (diabetic retinopathy), and in the elderly (age-related macular degeneration), despite current therapy. Although ablation of the retina reduces the incidence of blindness by suppressing the neovascular phase of ROP and diabetic retinopathy, the visual outcomes after treatment are often poor. Preventive therapy is required and will likely come from a better understanding of the pathophysiology of the disease.

引用

页码：139 / 149

页数：11

共 59 条

[1] Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate [J].

Adamis, AP ;

Shima, DT ;

Tolentino, MJ ;

Gragoudas, ES ;

Ferrara, N ;

Folkman, J ;

DAmore, PA ;

Miller, JW .

ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) :66-71

[2] SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].

AIELLO, LP ;

PIERCE, EA ;

FOLEY, ED ;

TAKAGI, H ;

CHEN, H ;

RIDDLE, L ;

FERRARA, N ;

KING, GL ;

SMITH, LEH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461

[3] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[4] VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].

ALON, T ;

HEMO, I ;

ITIN, A ;

PEER, J ;

STONE, J ;

KESHET, E .

NATURE MEDICINE, 1995, 1 (10) :1024-1028

[5] OXYGEN AND GROWTH AND DEVELOPMENT OF RETINAL VESSELS - IN VIVO AND IN VITRO STUDIES - 20 FRANCIS I PROCTOR LECTURE [J].

ASHTON, N ;

PATH, FC .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 1966, 62 (03) :412-&

[6] Intravitreal growth factors in proliferative diabetic retinopathy: Correlation with neovascular activity and glycaemic management [J].

Boulton, M ;

Gregor, Z ;

McLeod, D ;

Charteris, D ;

JarvisEvans, J ;

Moriarty, P ;

Khaliq, A ;

Foreman, D ;

Allamby, D ;

Bardsley, B .

BRITISH JOURNAL OF OPHTHALMOLOGY, 1997, 81 (03) :228-233

[7] Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy -: A case-control study [J].

Burgos, R ;

Hernández, C ;

Mateo, C ;

Mesa, J ;

Cantón, A ;

Simó, R .

DIABETES CARE, 2000, 23 (01) :80-83

[8]

Chantelau E, 1997, BRIT J OPHTHALMOL, V81, P169

[9] The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I) [J].

Cheetham, TD ;

Connors, M ;

Clayton, K ;

Watts, A ;

Dunger, DB .

CLINICAL ENDOCRINOLOGY, 1997, 46 (04) :415-424

[10] The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes:: Evidence for in vivo biological activity [J].

Clemmons, DR ;

Moses, AC ;

McKay, MJ ;

Sommer, A ;

Rosen, DM ;

Ruckle, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (04) :1518-1524

← 1 2 3 4 5 6 →